

Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns

Chung-Ming Lo, PhD^{a,b}, Rui-Cian Weng, MS^{c,d}, Sho-Jen Cheng, MD^e, Hung-Jung Wang, MD^e, Kevin Li-Chun Hsieh, MD^{e,f,*}

Abstract

World Health Organization tumor classifications of the central nervous system differentiate glioblastoma multiforme (GBM) into wild-type (WT) and mutant isocitrate dehydrogenase (*IDH*) genotypes. This study proposes a noninvasive computer-aided diagnosis to interpret the status of *IDH* in glioblastomas from transformed magnetic resonance imaging patterns. The collected image database was composed of 32 WT and 7 mutant *IDH* cases. For each image, a ranklet transformation which changed the original pixel values into relative coefficients was 1st applied to reduce the effects of different scanning parameters and machines on the underlying patterns. Extracting various textural features from the transformed ranklet images and combining them in a logistic regression classifier allowed an *IDH* prediction. We achieved an accuracy of 90%, a sensitivity of 57%, and a specificity of 97%. Four of the selected textural features in the classifier (homogeneity, difference entropy, information measure of correlation, and inverse difference normalized) were significant ($P < .05$), and the other 2 were close to being significant ($P = .06$). The proposed computer-aided diagnosis system based on radiomic textural features from ranklet-transformed images using relative rankings of pixel values as intensity-invariant coefficients is a promising noninvasive solution to provide recommendations about the *IDH* status in GBM across different healthcare institutions.

Abbreviations: CAD = computer-aided diagnosis, D-2HG = D-2-hydroxyglutarate, GBM = glioblastoma multiforme, GLCM = gray-level co-occurrence matrix, GLRLM = gray-level run length matrix, *IDH* = mutant isocitrate dehydrogenase, MRI = magnetic resonance imaging, NPV = negative predictive value, PPV = positive predictive value, SD = standard deviation, T1WIs = T1-weighted images, TCGA = The Cancer Genome Atlas, TCIA = the Cancer Imaging Archive, WT = wild-type.

Keywords: isocitrate dehydrogenase, glioblastoma, computer-aided diagnosis, ranklet transformation, magnetic resonance imaging

1. Introduction

Glioblastoma multiforme (GBM) is the most common and most aggressive glioma in brain.^[1,2] Nearly 90% of GBMs are classified as primary, with the remaining 10% being secondary.

Editor: Jianxun Ding.

The authors have no funding and conflicts of interest to disclose.

^a Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, ^b Graduate Institute of Library, Information and Archival Studies, National Chengchi University, ^c Taiwan Instrument Research Institute, National Applied Research Laboratories, ^d Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, ^e Department of Medical Imaging, Taipei Medical University Hospital, ^f Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

* Correspondence: Kevin Li-Chun Hsieh, Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Xing St Taipei, Taiwan 11031, ROC (e-mail: kevinh9396@tmu.edu.tw).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lo CM, Weng RC, Cheng SJ, Wang HJ, Hsieh KLC. Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns. *Medicine* 2020;99:8(e19123).

Received: 31 May 2019 / Received in final form: 23 October 2019 / Accepted: 11 January 2020

<http://dx.doi.org/10.1097/MD.00000000000019123>

The prognosis of primary GBMs is grim despite advances in different therapies.^[3] Recent genomic characterization of both low- and high-grade gliomas showed frequent mutations in the isocitrate dehydrogenase 1 (*IDH1*) gene and its homolog, *IDH2*.^[4,5] These mutations impair *IDH*'s function, and result in accumulation of an oncogenic metabolite, D-2-hydroxyglutarate (D-2HG), within the tumor.^[5,6] This metabolite induces epigenetic changes that result in abnormal regulation of gene expressions and cellular differentiation, along with increased levels of hypoxia-inducible factor-1 α , which are all important elements of tumorigenesis.^[7–9] In the latest World Health Organization tumor classification of the central nervous system, GBMs are classified as wild-type (WT) *IDH* and mutant *IDH* GBMs.^[3] The mutant *IDH* GBMs are associated with better prognosis compared to their WT counterparts. *IDH* mutations were associated with prolonged progression-free survival and a trend for prolonged overall survival.^[10]

Currently, the most commonly applied method to detect *IDH* mutations in GBMs is an immunohistochemical analysis, in which a specific monoclonal antibody that recognizes the R132H amino acid mutation is applied. However, there are still diagnostic challenges because of the partial sampling of lesions and heterogeneity of tumors. Cryan et al also demonstrated a limitation of traditional *IDH1* antibody testing in terms of the sensitivity of the applied antibody.^[11] Moreover, it was proven that survival benefits associated with surgical strategies differ based on the *IDH1* genotype in malignant astrocytomas.^[12]

Therefore, a noninvasive method for preoperative prediction of the *IDH* genotype is important for surgical planning and research in understanding the biology of gliomas.

Magnetic resonance (MR) imaging (MRI) is an ideal solution for characterizing physiologic and molecular features of GBMs in a noninvasive manner.^[13,14] MRI equipped with specialized MR spectroscopic techniques was proved to be able to detect the in vivo accumulation of D-2HG, the oncometabolite produced from *IDH* mutations.^[15,16] Other MRI techniques, including perfusion and diffusion imaging, were also proposed to distinguish differences between WT and mutant *IDH* GBMs.^[17] Interpretation of the *IDH* status from MRIs can be realized from heterogeneous patterns within the tumor area. With the development of textural analyses, pixel-wise correlations present tiny details between tissues which might not be readily recognized by human beings. Additionally, the quantification process has strengthened the clinical utility of MRI.

To provide a more-fitting interpretation of tissue compositions, the quantified texture extracted from the tumor area can be combined in an artificial intelligence classifier to achieve a computer-aided diagnosis (CAD) system.^[18,19] However, Buch et al proposed that a lack of standardized scanning protocols for images collected from different institutes may lead to variations in textural analytical features irrespective of the internal architecture.^[20] To reduce the effects of such confounding factors, this study proposed a specific CAD model based on ranklet transformation to interpret the *IDH* status through a sophisticated integration of numerous textural features. The ranklet transformation uses relative rankings of pixel values in a local area as intensity-invariant coefficients to emphasize the underlying image pattern. The resulting estimate of the likelihood of there being an *IDH* mutation facilitates the clinical diagnosis in a more-reliable way.

2. Materials and methods

2.1. The cancer genome atlas and the cancer imaging archive

The data set used in the experiment was from the cancer imaging archive (TCIA; <http://cancerimagingarchive.net/>) established by the National Cancer Institute. Patients who underwent MRI examinations also have *IDH* mutation information in the cancer genome atlas (TCGA). GBM cases were composed of 32 WT *IDH* and 7 mutant *IDH* forms. Materials provided by TCIA and TCGA were used in compliance with all applicable laws, regulations, and policies based on Washington University School of Medicine IRB Protocol 201108194. The necessary approvals, authorizations, participant assurances, informed consent documents, and institutional review board approvals in every institution related to this research were acquired.^[21]

The MRIs of 32 WT *IDH* GBMs were obtained from Case Western and Henry Ford Hospitals. Seven mutant *IDH* GBMs were collected from Emory University, Henry Ford Hospital, and Fondazione IRCCS Istituto Neurologico C. Besta. These cases were determined after exploring 291 GBM cases in TCIA where only 15 (5.15%) were found to be mutant *IDH* GBMs. Among these 15, only 7 cases with preoperative contrast-enhanced T1-weighted images (T1WIs) were enrolled in the experiment. *IDH1* R132G mutation was detected in one case, and the remaining cases had the *IDH1* R132H mutation. No *IDH2* mutation case can be found in TCIA. The WT *IDH* cases

Table 1
Demographic information of the cohort.

	Age, yr	Sex	Tumor laterality	Tumor location
WT <i>IDH</i>	62 ± 12	9 females, 23 males	20 right 12 left	11 frontal 18 temporal 2 parietal 1 occipital
Mutant <i>IDH</i>	36 ± 15	2 females, 5 males	3 right 4 left	3 frontal 2 temporal 0 parietal 2 occipital

IDH = isocitrate dehydrogenase; WT = wild-type.

were obtained from 2 of the 4 institutes through consecutive selection in TCGA archive. Due to the insufficient image quality, 8 of 40 WT *IDH* cases were excluded. Patient and tumor characteristics are listed in Table 1.

2.2. Traditional interpretation by neuroradiologists

Since traditional radiographic features on MRI have been proposed based on univariate analyses that *IDH1* mutant tumors were more frequently located at the frontal lobe adjacent to the subventricular zone.^[22,23] *IDH1* mutant GBMs more likely exhibit a unilateral growth pattern, sharp tumor margins, a lower volume of enhancement, and a homogeneous signal intensity.^[24] Three neuroradiologists (KH, with 14 years of experience, HJW, with 17 years of experience, and SJC, with 25 years of experience) were asked to determine the *IDH* status of the recruited cases based on the abovementioned features. Differences of opinion were resolved by consensus for determining the final *IDH* status.

2.3. Transformed MRI textures

2.3.1. Tumor segmentation. Contrast-enhanced axial T1WIs were used for feature extraction for interpreting the *IDH* status. A board-certified neuroradiologist (KH), blinded to the *IDH* status information, delineated the slices with the largest axial cross-section as the representative tumor area for subsequent feature extraction for each glioblastoma. Intensity normalization, which stretched the gray-level distribution to the entire 8-bit value range (0–255) in individual images, was performed prior to contour delineation to enhance the contrast between the tumor and normal brain tissues. Contours were manually delineated with OsiriX MD (version 9.0; Pixmeo, Geneva, Switzerland). Image pixels enclosed by the delineated tumor region defined the tumor area and were used for subsequent processing and feature extraction. Figure 1A and C shows the WT *IDH* and mutant *IDH*, respectively. The corresponding tumor areas are illustrated in Figure 1B and D.

2.3.2. Ranklet transformation. The image textural analysis is widely used to characterize tissues in CAD systems. Due to variations in gray-scale distributions under different scanner models and settings, textural features might not perform as well as shape features. Shape features can be extracted because the brightness between the tumor boundary and background tissues is clear. However, the contrast between pixels in a texture pattern may not strong enough. This phenomenon limits the usefulness of applying textural features in clinical diagnoses. To make the textural features




Figure 1. A wild-type (WT) isocitrate dehydrogenase (*IDH*) (A) and a mutant *IDH* genes (C) in magnetic resonance image. (B) and (D) are extracted tumors (<http://cancerimagingarchive.net/>; "License" and the CC BY license, <https://creativecommons.org/licenses/by/3.0/>).

more reliable, ranklet transformation was proposed to change the original pixel values into relative coefficients.^[25] Ranklet transformation changes the absolute gray-scale values into relative ranklet coefficients calculated by the ranked values of pixels in the local pattern to enhance the contrast.

Ranklet transformation is orientation selective. If we simply separate patterns into different orientations for the textural analysis, the use of the three orientations, that is, vertical, horizontal, and diagonal, would be sufficient. The relative difference between 2 sides of a block in the vertical, horizontal, and diagonal orientations can reveal corresponding fluctuations. These blocks were separated from the original image under a resolution value (4×4 in the experiment). Each block was then divided into 2 subsets, X and Y, according to the selected orientations, as shown in Figure 2. Divisions, including vertical, horizontal, and diagonal orientations, were from Haar functions used in the wavelet transform^[26] to show local

patterns. The number of pixel pairs (P_H, P_L) in each block was determined; that is, the relative rank of pixels of P_H in a subset such as X is higher than that of P_L in the other subset such as Y. If there are C pixels in a block, $C/2 \times C/2 = C^2/4$ comparisons are calculated. The resulting number was normalized to between -1 and 1 . The ranklet transformation coefficient, R_O , is formulated as follows:

$$R_O = \frac{\sum \rho \in Y_O \pi(\rho) - C/4(C/2 + 1)}{C^2/8} - 1, O = V, H, D. \quad (1)$$

In subset Y_O , pixel ranks $\pi(p)$ are summed. If more pixels in Y_O are higher than those in X_O , R_O is close to 1. Otherwise, it is close to -1 . For patterns without strong variations, the coefficient is close to 0. By replacing the original pixel values by ranklet coefficients, the regularity correlation in the local pattern can be observed as shown in Figure 3.




Figure 2. Illustration of three orientations used in the ranklet transformation, including vertical, horizontal, and diagonal patterns.

2.3.3. Textural features. The ranklet transformation changes the presentation of an image pattern. To extract textural features from the transformed image pattern, a computational statistical analysis is needed to quantify the pattern information to become textural features. As described in detail previously,^[27-29] the gray-level co-occurrence matrix (GLCM) was proposed to be promising in interpreting image textures. The GLCM texture describes the local pattern formed by correlations between adjacent pixels and is used in various CAD systems for tumor classification.^[30] In general, the 0 to 255 gray-scale values are reduced to generate an image, G , with fewer intensity bins for computational efficiency. A matrix is then established by counting the co-occurrence frequencies of two adjacent pixel values (i and j) at a distance d and direction θ .^[27] Settings used in this experiment were $d=1$ and $\theta=0^\circ, 45^\circ, 90^\circ$, and 135° , which were individually calculated and averaged in combination. In total, 14 GLCM textural features were implemented as below:

$$\text{Auto correlation} = \sum_i \sum_j (p_x - \mu_x)(p_y - \mu_y) / \sigma_x \sigma_y \quad (1)$$

$$\text{Contrast} = \sum_n n^z \left\{ \sum_i \sum_j p(i, j) \right\}, \quad |i - j| = n \quad (2)$$

$$\text{Correlation} = \frac{\sum_i \sum_j (i - \mu_x)(j - \mu_y) p(i, j)}{\sigma_x \sigma_y} \quad (3)$$

$$\text{Cluster prominence} = \sum_i \sum_j (i + j - \mu_x - \mu_y)^4 p(i, j) \quad (4)$$

$$\text{Cluster shade} = \sum_i \sum_j (i + j - \mu_x - \mu_y)^3 p(i, j) \quad (5)$$

$$\text{Dissimilarity} = \sum_i \sum_j p(i, j) |i - j| \quad (6)$$

$$\text{Energy} = \sum_i \sum_j p(i, j)^2 \quad (7)$$

$$\text{Energy} = - \sum_i \sum_j p(i, j) \log(p(i, j)) \quad (8)$$

$$\text{Homogeneity} = - \sum_i \sum_j \frac{1}{1 + |i - j|} p(i, j) \quad (9)$$

$$\text{Difference variance} = \sum_i i^2 p_{x-y}(i) \quad (10)$$

$$\text{Difference entropy} = - \sum_i p_{x-y}(i) \log(p_{x+y}(i)) \quad (11)$$




Figure 3. Resulting images after transforming the original tumor image in Figure 1B to a ranklet coefficient image. (A) Transformed vertical image, (B) transformed horizontal image, and (C) transformed diagonal image (<http://cancerimagingarchive.net/>; "License" and the CC BY license, <https://creativecommons.org/licenses/by/3.0/>; tumor areas in this figure were extracted from original images).

$$\begin{aligned}
 & \frac{HXY - HXY1}{\max(HX, HY)} \\
 & HXY = (8), \\
 \text{Information measure} & HXY1 = - \sum_i \sum_j p(i, j) \log(p_x(i)p_y(j)) \\
 \text{of correlation} = & \\
 & HX = \text{entropy of } p_x, \\
 & HY = \text{entropy of } p_y
 \end{aligned}
 \tag{12}$$

$$\text{Inverse difference normalized} = \sum_i \sum_j \frac{1}{1 + |i - j|} p(i, j) \tag{13}$$

$$\text{Inverse difference moment} = \sum_i \sum_j \frac{1}{1 + (i - j)^2} p(i, j) \tag{14}$$

where $\mu_x, \mu_y, \sigma_x,$ and σ_y are the mean and standard deviation (SD) of the marginal distributions of $p(i, j|d, \theta)$.

$$\mu_x = \sum_i i \sum_j p(i, j), \mu_y = \sum_j j \sum_i p(i, j) \tag{15}$$

$$\sigma_x^2 = \sum_i (i - \mu_x)^2 \sum_j p(i, j), \sigma_y^2 = \sum_j (j - \mu_y)^2 \sum_i p(i, j) \tag{16}$$

Gray-level run length matrix (GLRLM)^[31] was also used in the experiment for comparison. GLRLM gives the number of homogeneous runs for each gray level. The setting of GLRLM is slightly different from GLCM; GLRLM does not calculate the pair of gray scales owned, but has a length.

2.4. Statistical analysis

Textural features extracted from transformed MRIs, including vertical, horizontal, and diagonal feature sets, were used in the experiment to interpret the *IDH* status. Each feature set had 14 GLCM textural features describing correlations between pixels and their neighbors. With next-generation sequencing-based molecular profiles as the gold standard, features in individual categories were combined together in machine learning classifiers including logistic regression,^[32] k nearest neighbor (KNN),^[33] and support vector machine (SVM).^[34] Using stepwise backward elimination, the most favorable combination of features was selected with the lowest error rate. Meanwhile, the corresponding fitting model was validated using the leave-one-out method^[35] to determine its generalizability. While *N* is the total number of cases, an individual case was picked in each iteration and was used to validate the trained model from the other *N* - 1 cases. As a result, each case had a probability of being an *IDH* mutation according to the fitting model. Performances between different feature sets, such as the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were

compared using a Chi-squared test in SPSS (vers. 16 for Windows; SPSS, Chicago, IL, USA). The distinguishing ability of using a single feature was also tested. After evaluating whether the distribution was normal by the Kolmogorov-Smirnov test,^[35-37] Student *t* test^[35-37] was used to test features with normal distributions, and non-normal features were tested by the Mann-Whitney *U* test.^[35-37] A *P* value of <.05 indicated statistical significance.

3. Results

3.1. Machine learning interpretation

This study proposed interpreting the characteristics of glioblastomas in MRIs to predict the status of *IDH* mutations. Via ranklet transformation and GLCM textural features, 3 feature sets were extracted: vertical, horizontal, and diagonal orientations of tumor patterns. Each feature set had 14 GLCM textural features implemented (autocorrelation, contrast, correlation, cluster prominence, cluster shading, dissimilarity, energy, entropy, homogeneity, difference variance, difference entropy, information measure of correlation, inverse difference normalized, and inverse difference moment)^[27-29] that were combined in a logistic regression classifier to generate the prediction model. Ranklet features with the vertical orientation achieved the best performance and compared to conventional GLCM features in Table 2. Nevertheless, ranklet features obtained 90% (35/39) accuracy which is higher than GLCM features: 85% (33/39). KNN and SVM achieved accuracy of 82.1%, respectively, while the texture features of GLRLM is 85%. The GLCM features selected in the classifier included the homogeneity, difference variance, difference entropy, information measure of correlation, inverse difference normalized, and inverse difference moment. Homogeneity expresses whether tissue compositions are similar or diverse. The difference variance indicates the variance between the co-occurrence probabilities along different (*x* and *y*) axes. Correlation is the gray-scale linear dependence between a pixel and its adjacent neighbors. The inverse difference moment is also proposed to estimate the homogeneity of an image pattern.^[38] Taking Figure 1D as an example, the result showed a homogeneity of 0.987 and a difference variance of 0.029 which led to a 99% probability of being a mutant *IDH*. Four of them were statistically significant (*P* < .05) in distinguishing WT *IDH* and mutant *IDH*, while the other 2 features were nearly significant by Student *t* test (Table 3). Figure 4 shows that the use of ranklet transform can help to reduce the influence of varying scanning parameters and machines cross institutions on the image intensity. With respect to the feature, cluster prominence, the SD between the original image, brightness adjustment, and contrast enhancement is 126. After ranklet transformation, SD ranged from 0.09 to 0.27 for transformed original image, brightness adjustment, and contrast enhancement.

Table 2
Performances of different image orientation features for predicting isocitrate dehydrogenase mutations.

	Ranklet features	GLCM features	GLRLM features	KNN	SVM
Accuracy	90% (35/39)	85% (33/39)	85% (33/39)	82% (32/39)	82% (32/39)
Sensitivity	57% (4/7)	86% (6/7)	29% (2/7)	14% (1/7)	14% (1/7)
Specificity	97% (31/32)	84% (27/32)	97% (31/32)	97% (31/32)	97% (31/32)
PPV	80% (4/5)	55% (6/11)	67% (2/3)	50% (1/2)	50% (1/2)
NPV	91% (31/34)	96% (27/28)	86% (31/36)	97% (31/32)	97% (31/32)

GLCM = gray-level co-occurrence matrix, GLRLM = gray-level run length matrix, KNN = k nearest neighbor, NPV = negative predictive value, PPV = positive predictive value, SVM = support vector machine.

Table 3
The selected textural features in the logistic regression classifier and the corresponding *P* values evaluated using Student *t* test.

Feature	WT <i>IDH</i> Mean ± SD	Mutant <i>IDH</i> Mean ± SD	<i>P</i> value
Homogeneity	0.991 ± 0.003	0.988 ± 0.004	<.05*
Difference variance	0.021 ± 0.010	0.029 ± 0.012	.06
Difference entropy	0.085 ± 0.033	0.114 ± 0.036	<.05*
Information measure of correlation	0.427 ± 0.075	0.497 ± 0.067	<.05*
Inverse difference normalized	0.998 ± 0.001	0.997 ± 0.001	<.05*
Inverse difference moment	0.9996 ± 0.001	0.9995 ± 0.001	.06

IDH = isocitrate dehydrogenase, *SD* = standard deviation, *WT* = wild-type.
* A *P* value of <.05 indicates a statistically significant difference.

3.2. Traditional interpretation

To determine if the proposed transformed radiomic patterns have better accuracy for the *IDH* mutation status than traditional interpretations, 3 neuroradiologists were asked to decide the *IDH* status of the recruited cases based on the MRI observation. Results showed that all five performance indices of the proposed CAD system were better than the traditional interpretation of the *IDH* status of GBM. The differences of accuracy and PPV were

Table 4
Performance comparisons between three radiologists and the proposed computer-aided diagnosis (CAD) in classifying the isocitrate dehydrogenase status.

	Radiologists	CAD	Radiologists vs CAD (<i>P</i> value)
Accuracy	72% (28/39)	90% (35/39)	.0443*
Sensitivity	14% (1/7)	57% (4/7)	.0943
Specificity	84% (27/32)	97% (31/32)	.0863
PPV	17% (1/6)	80% (4/5)	.0357*
NPV	82% (27/33)	91% (31/34)	.2614

NPV = negative predictive value, PPV = positive predictive value.
* *P* < .05 indicates a statistically significant difference.

especially significant better (90% vs 72% and 80% vs 17%, respectively) as shown in Table 4. The individual performance of the 3 radiologists is listed in Table 5.

4. Discussion

Several frequent mutations in *IDH* genes were unveiled by exomic sequencing,^[4,5] which impaired *IDH1*'s function of converting isocitrate to α-ketoglutarate and confer a gain of

ROI	Original	Brightness Adjustment	Contrast Enhancement	Cluster Prominence (SD)
MRI Image				126
V				0.27
H				0.23
D				0.09

Figure 4. The standard deviations of feature values obtained from image processings and Ranklet transformation (<http://cancerimagingarchive.net/>; "License" and the CC BY license, <https://creativecommons.org/licenses/by/3.0/>; tumor areas in this figure were extracted from original images).

Table 5**Performances of three radiologists in classifying the isocitrate dehydrogenase status.**

	Radiologist_A	Radiologist_B	Radiologist_C
Accuracy	79% (31/39)	74% (29/39)	64% (25/39)
Sensitivity	14% (1/6)	14% (1/7)	29% (2/7)
Specificity	94% (30/32)	88% (28/32)	72% (23/32)
PPV	33% (1/3)	20% (1/5)	18% (2/11)
NPV	83% (30/36)	82% (28/34)	82% (23/28)

NPV = negative predictive value, PPV = positive predictive value.

function in converting α -ketoglutarate to D-2HG.^[5,6] D-2HG is thought to be an oncometabolite. It can induce epigenetic changes that result in dysregulation of gene expressions and disturbed control of cellular differentiation, leading to tumorigenesis.^[7,8] IDH mutations are highly selective molecular biomarkers of secondary disease because these mutations are mainly observed in secondary GBMs.^[8,9] Therefore, tumors with mutant *IDH* genes are believed to have a more heterogeneous compositions and imaging characteristics because of the stepwise gliomagenesis pattern of secondary GBMs.^[17]

According to our previous study,^[39] textural features describing heterogeneous patterns were extracted from MRIs and combined in the classifier to correctly classify 33 of 39 *IDH* mutation types. The difference in accuracy between our previous study^[39] and this study was not significant. Nevertheless, this study further achieved 90% accuracy which is higher than previous 85%. The proposed ranklet-transformed features achieved less *P* values or very close to .05 which were better than our previous results using pure textural features (Table 3). Several classifiers were tried including KNN, and support vector machine with or without principal components analysis to explore any better feature combinations. The resulting highest accuracy is 82.1% which is no better than the proposed method. Other texture features such as GLRLM was also used in the experiment. With ranklet transformation or without, GLRLM only achieved the best accuracy of 85%. The matrix compositions are different from GLCM. The use of ranklet may be only suitable for matrix form of GLCM.

Image intensity variance caused by different scanning parameters and machines may have an influence on the diagnosis. Ranklet-transformed textural features emphasize local contrasts using relative coefficients that may better present specific heterogeneous patterns. This technique was 1st applied to reduce the effects of different scanning parameters and machines on the underlying patterns. As shown in Figure 4, the SDs between various gray-scale compositions such as the variations of brightness and contrast were eliminated after ranklet transformation. Additionally, our results depicted that tumors with *IDH* mutations had lower homogeneity. The combination of these imaging characteristics suggested that mutant *IDH* GBMs tended to have more-heterogeneous imaging intensities, which also implied their multistage tumorigenic behaviors.

Using a radiomic model for predicting *IDH* mutations provides a connection between intuitive vision and precision medicine. Tumor characteristics can be mapped and quantified by applying high throughput radiomic analysis on routine MRI examination without requiring a risky surgery. However, this preliminary study was limited by the insubstantial number of mutant *IDH* cases. More cases should be collected in further studies to support

the above results. However, we did our best to enroll cases from 4 hospitals and maintained a ratio between WT *IDH* and mutant *IDH* to provide these preliminary results. Another limitation is that only contrast-enhanced T1WIs were used in our analysis, which are insufficient to characterize peritumoral edema. Nevertheless, *IDH* mutations are linked to angiogenesis,^[9] and it was reported that the activity of the angiogenesis module in a tumor was associated with the signal intensity of contrast enhancement.^[40,41] Therefore, it is reasonable that the imaging features extracted from contrast-enhanced T1WIs can be applied to predict whether GBMs have *IDH* mutations. The impact of other MRI sequences including apparent diffusion coefficient map, perfusion-weighted imaging, and diffusion tensor imaging will be further investigated.

5. Conclusion

A CAD system was proposed to interpret the status of *IDH* in glioblastomas from transformed MRI patterns. Quantitative textural features extracted from the transformed ranklet images achieved an accuracy of 90%, a sensitivity of 57%, and a specificity of 97%. The system based on textural features from ranklet-transformed images is a promising noninvasive method to provide suggestions about the *IDH* status in GBM.

Acknowledgments

The authors thank the Ministry of Science and Technology, Taiwan (MOST104-2218-E-038-004 and 105-2314-B-038-049), and Taipei Medical University and Taipei Medical University Hospital (106TMU-TMUH-20) for financially supporting this study.

Author contributions

Conceptualization: Kevin Li-Chun Hsieh.

Data curation: Sho-Jen Cheng, Hung-Jung Wang.

Funding acquisition: Rui-Cian Weng.

Methodology: Chung-Ming Lo.

Resources: Rui-Cian Weng.

Software: Chung-Ming Lo.

Validation: Sho-Jen Cheng, Hung-Jung Wang.

Writing – original draft: Chung-Ming Lo, Kevin Li-Chun Hsieh.

Writing – review & editing: Kevin Li-Chun Hsieh.

References

- [1] Wen PY, Kesari S. Malignant gliomas in adults. *N Engl J Med* 2008;359:492–507.
- [2] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 2007; 114:97–109.
- [3] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 2016;131:803–20.
- [4] Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–12.
- [5] Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765–73.
- [6] Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739–44.
- [7] Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* 2012;483:474–8.

- [8] Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* 2012;483:479–83.
- [9] Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. *J Clin Oncol* 2007;25:2288–94.
- [10] Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. *J Clin Oncol* 2009;27:5743–50.
- [11] Cryan JB, Haidar S, Ramkissoon LA, et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. *Oncotarget* 2014;5:8083–92.
- [12] Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. *Neuro Oncol* 2014;16:81–91.
- [13] Jackson A, O'Connor JP, Parker GJ, et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. *Clin Cancer Res* 2007;13:3449–59.
- [14] Jain R, Poisson L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. *Radiology* 2013;267:212–20.
- [15] Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. *Sci Transl Med* 2012;4:116ra4.
- [16] Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 2012;18:624–9.
- [17] Lee S, Choi SH, Ryoo I, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. *J Neurooncol* 2015;121:141–50.
- [18] Chang R-F, Lee C-C, Lo C-M. Computer-aided diagnosis of different rotator cuff lesions using shoulder musculoskeletal ultrasound. *Ultrasound Med Biol* 2016;42:2315–22.
- [19] Hsieh KL-C, Lo C-M, Hsiao C-J. Computer-aided grading of gliomas based on local and global MRI features. *Comput Methods Programs Biomed* 2017;139:31–8.
- [20] Buch K, Li B, Qureshi MM, et al. Quantitative assessment of variation in CT parameters on texture features: pilot study using a nonanatomic phantom. *AJNR Am J Neuroradiol* 2017;38:981–5.
- [21] McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061–8.
- [22] Ellingson BM, Lai A, Harris RJ, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. *AJNR Am J Neuroradiol* 2013;34:533–40.
- [23] Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. *J Clin Oncol* 2011;29:4482–90.
- [24] Ellingson BM. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. *Curr Neurol Neurosci Rep* 2015;15:506.
- [25] Lo C-M, Moon WK, Huang C-S, et al. Intensity-invariant texture analysis for classification of bi-rads category 3 breast masses. *Ultrasound Med Biol* 2015;41:2039–48.
- [26] Mallat SG. A theory for multiresolution signal decomposition: the wavelet representation. *IEEE* 1989;11:674–93.
- [27] Haralick RM, Shanmugam K, Dinstein IH. Textural features for image classification. *IEEE* 1973;SMC-3:610–21.
- [28] Clausi DA. An analysis of co-occurrence texture statistics as a function of grey level quantization. *Canad J Remote Sens* 2002;28:45–62.
- [29] Soh L-K, Tsatsoulis C. Texture analysis of SAR sea ice imagery using gray level co-occurrence matrices. *IEEE* 1999;37:780–95.
- [30] Lo C-M, Chen R-T, Chang Y-C, et al. Multi-dimensional tumor detection in automated whole breast ultrasound using topographic watershed. *IEEE Trans Med Imaging* 2014;33:1503–11.
- [31] Mohanty AK, Beberta S, Lenka SK. Classifying benign and malignant mass using GLCM and GLRLM based texture features from mammogram. *Int J Eng Res Appl* 2011;1:687–93.
- [32] Menard S. *Applied Logistic Regression Analysis*. Vol. 106. US: Sage; 2002.
- [33] Peterson LE. K-nearest neighbor. *Scholarpedia* 2009;4:1883.
- [34] Suykens JA, Vandewalle J. Least squares support vector machine classifiers. *Neural Proces Lett* 1999;9:293–300.
- [35] Field AP. *Discovering Statistics Using SPSS*. 3rd ed Los Angeles, CA: SAGE Publications; 2009.
- [36] Hsieh KL-C, Chen C-Y, Lo C-M. Quantitative glioma grading using transformed gray-scale invariant textures of MRI. *Comp Biol Med* 2017;83:102–8.
- [37] Moon WK, Chen I-L, Chang JM, et al. The adaptive computer-aided diagnosis system based on tumor sizes for the classification of breast tumors detected at screening ultrasound. *Ultrasonics* 2017;76:70–7.
- [38] Sharma N, Ray AK, Sharma S, et al. Segmentation and classification of medical images using texture-primitive features: Application of BAM-type artificial neural network. *J Med Phys* 2008;33:119–26.
- [39] Hsieh KL, Chen CY, Lo CM. Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. *Oncotarget* 2017;8:45888–97.
- [40] Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proc Natl Acad Sci U S A* 2008;105:5213–8.
- [41] Pope WB, Chen JH, Dong J, et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis 1. *Radiology* 2008;249:268–77.